CPL500036 Phase 2 trial reaches completed status
The study compared low and high doses with placebo while assessing safety, efficacy and pharmacokinetics in levodopa-induced dyskinesia.

CPL500036's Phase 2 study in levodopa-induced dyskinesia was listed as completed in a ClinicalTrials.gov registry record published Nov. 12.
The mid-stage human trial matters because it moves Celon Pharma SA's drug candidate past a designed test of safety, efficacy and pharmacokinetics, compared with placebo and two dose levels.
The registry identifies three study arms: low-dose CPL500036, high-dose CPL500036 and placebo. Pharmacokinetics refers to how a drug moves through the body, including absorption and clearance.
Celon Pharma SA and the National Center for Research and Development, Poland, are listed as sponsors of the study. Levodopa-induced dyskinesia is an involuntary movement complication associated with levodopa treatment in Parkinson disease.
Completion of a Phase 2 trial does not, by itself, show that a drug is effective or safe enough for approval.
Investors, clinicians and patients tracking Parkinson-related movement-disorder treatments will need the reported efficacy and safety data before judging whether CPL500036 can proceed further in clinical development.
Source: clinical registry, ClinicalTrials.gov, Nov. 12
Atlas360 reports health research and does not provide medical advice.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- NIH-funded researchers map basal ganglia at single-cell resolution
- PFOS levels track 93% higher aggressive breast cancer rate
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

